SCHEMBL6099748

SCHEMBL6099748

Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1ccc(O)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNB2 O95067 8/20 0.81
CDK1 P06493 8/20 0.81
CCNB1 P14635 8/20 0.81
CCNB3 Q8WWL7 8/20 0.81
JAK2 O60674 12/20 0.67
CDK4 P11802 3/20 0.67
CCNA2 P20248 3/20 0.67
CCND1 P24385 3/20 0.67
CDK2 P24941 3/20 0.67
MAPK3 P27361 3/20 0.67
MAPK1 P28482 3/20 0.67
KDR P35968 3/20 0.67
CSNK1A1 P48729 3/20 0.67
CSNK1D P48730 3/20 0.67
CSNK1E P49674 3/20 0.67
GSK3A P49840 3/20 0.67
GSK3B P49841 3/20 0.67
CSNK1G2 P78368 3/20 0.67
CCNA1 P78396 3/20 0.67
CSNK1G1 Q9HCP0 3/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5986060 0.90 CCNB2 (0.79) CCNB2CDK1CCNB1CCNB3JAK2
SCHEMBL5726202 0.89 CCNB2 (1.00) CCNB2CDK1CCNB1CCNB3JAK2
SCHEMBL5726369 0.88 CCNB2 (0.81) CCNB2CDK1CCNB1CCNB3JAK2
SCHEMBL6102916 0.88 CCNB2 (0.87) CCNB2CDK1CCNB1CCNB3JAK2
SCHEMBL6101131 0.87 CCNB2 (0.74) CCNB2CDK1CCNB1CCNB3JAK2
SCHEMBL6102097 0.87 CCNB2 (0.74) CCNB2CDK1CCNB1CCNB3JAK2
SCHEMBL1167536 0.84 CCNB2 (0.58) CCNB2CDK1CCNB1CCNB3JAK2
SCHEMBL1167710 0.83 CDK1 (0.69) CCNB2CDK1CCNB1CCNB3JAK2
SCHEMBL5964885 0.83 CCNB2 (0.72) CCNB2CDK1CCNB1CCNB3JAK2
SCHEMBL5727014 0.83 CCNB2 (0.80) CCNB2CDK1CCNB1CCNB3JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060100259-A1 Process for the preparation of substituted triazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100259-A1 Process for the preparation of substituted triazole compounds TESK2, MAP2K2, TESK1 CCNB2 1767/4885CDK1 262/4885CCNB1 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.